Verity Asset Management’s Sinovac Biotech, Ltd SVA Stock Holding History

Verity Asset Management’s Portfolio SVA Stock Details SVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-13,542	Closed	-$98K	–	168
2017 Q3	$98K	Sell	13,542 -5,604	-29%	-$38.3K	0.07%	117
2017 Q2	$129K	Sell	19,146 -8,456	-31%	-$46.3K	0.1%	114
2017 Q1	$158K	Buy	+27,602	New	+$160K	0.13%	115
2016 Q3	$175K	Buy	+29,726	New	+$175K	0.16%	105
2016 Q2	–	Sell	-27,396	Closed	-$175K	–	127
2016 Q1	$175K	Buy	27,396 +2,651	+11%	+$15.9K	0.2%	78
2015 Q4	$142K	Sell	24,745 -9,487	-28%	-$51.1K	0.16%	64
2015 Q3	$174K	Sell	34,232 -1,652	-5%	-$8.75K	0.17%	83
2015 Q2	$188K	Buy	35,884 +18,213	+103%	+$96.2K	0.17%	84
2015 Q1	$88K	Buy	+17,671	New	+$87K	0.09%	79

Other funds holding SVA

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NAH

Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return

GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

FIM

Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

SIM

Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Verity Asset Management's SVA Position: Q4 2017 in Review

Verity Asset Management sold out of Sinovac Biotech, Ltd (SVA) in Q4 2017, closing a stake of 13,542 shares — an estimated $98K sold.

Verity Asset Management first reported a position in SVA in Q1 2015 and held it in 9 quarters. The position peaked at $188K in Q2 2015. 31 funds tracked by Wall St. Rank hold SVA as of Q4 2017.

Verity Asset Management reported no remaining Sinovac Biotech, Ltd position as of Q4 2017 after selling out during the quarter.
Verity Asset Management sold 13,542 Sinovac Biotech, Ltd shares in Q4 2017, an estimated $98K.
Verity Asset Management first reported a position in Sinovac Biotech, Ltd in Q1 2015 and held it in 9 quarters.
Verity Asset Management's Sinovac Biotech, Ltd position peaked at $188K in Q2 2015.
31 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q4 2017.

Based on Verity Asset Management's 13F filing for Q4 2017, filed 7 Feb 2018.